Syngene stock price dropped after management issued cautious outlook during quarterly results. The company has reduced FY24 guidance due to slowdown in the US biotech segment.
Market analyst Mitesh Thakkar has suggested four BUY Calls and no SELL Call for today’s trading session, indicating a bullish outlook for markets today.